Combination chemotherapy with oral etoposide

David H. Johnson, John D. Hainsworth, Kenneth R. Hande, F. Anthony Greco

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Chronic administration of etoposide over multiple days has proved to be an effective schedule against a variety of neoplasms. The usual duration of etoposide administration is 3 to 5 days. However, recent studies have demonstrated this agent can be administered for up to 21 consecutive days with acceptable toxicity. Studies are currently under way to determine whether more protracted etoposide administration will prove to be more efficacious in the management of selected malignancies. Previous work at our institution has confirmed the activity of protracted administration of single-agent etoposide against small cell lung cancer and non-small cell lung cancer. More recently, we have combined either cisplatin or carboplatin with etoposide given orally for 21 consecutive days in phase II trials in patients with small cell lung cancer and non-small cell lung cancer. The results of these trials are reviewed.

Original languageEnglish (US)
Pages (from-to)19-24
Number of pages6
JournalSeminars in oncology
Volume19
Issue number6 SUPPL. 14
StatePublished - Dec 1992

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Combination chemotherapy with oral etoposide'. Together they form a unique fingerprint.

  • Cite this

    Johnson, D. H., Hainsworth, J. D., Hande, K. R., & Greco, F. A. (1992). Combination chemotherapy with oral etoposide. Seminars in oncology, 19(6 SUPPL. 14), 19-24.